Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07634471 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)

StatusRecruiting
PhasePhase 2/3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial sites expanded: 26 → 32 locations
  2. Study sites: 26 to 27
  3. Study sites: 25 to 26
  4. Lead sponsor: Merck Sharp & Dohme LLC to Merck Sharp & Dohme LLC Study sites: 24 to 25 · Eligibility criteria expanded, about 20 words · Secondary endpoints: details revised at 6 of 15 entries Show 3 more changesShow less
    • Study sites: 24 to 25
    • Eligibility criteria expanded, about 20 words
    • Secondary endpoints: details revised at 6 of 15 entries
  5. Trial sites expanded: 21 → 24 locationsv13
Show 3 earlier versionsHide 3 earlier versions
  1. Study sites: 19 to 21v12
  2. Study sites: 17 to 19v11
  3. Study sites: 16 to 17v10
  1. Trial sites expanded: 13 → 16 locationsv9
  2. Study sites: 11 to 13v8
  3. Study sites: 10 to 11v7
  4. Study sites: 8 to 10v6
  5. Start date changed from estimate of Jul 6, 2026 to Jun 22, 2026v5
  6. Trial sites expanded: 5 → 8 locationsv4
  7. Trial sites expanded: 2 → 5 locationsv3
  8. Recruitment opened Study sites: 0 to 2v2 Show 1 more changeShow less
    • Study sites: 0 to 2
  9. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Researchers are looking for new ways to treat follicular lymphoma (FL). A standard (usual) treatment for FL includes a targeted therapy called rituximab and chemotherapy. In this study, researchers want to learn if giving a study medicine called MK-1045 and rituximab can treat FL. MK-1045 is a type of treatment called immunotherapy. The goals of this study are to learn: * About the safety of MK-1045 and rituximab, and if people tolerate them when given together * If people who receive MK-1045 and rituximab have the cancer go away * If people who receive MK-1045 and rituximab live longer without their cancer getting worse compared to those who receive standard treatment (rituximab and chemotherapy)
Trial Details
NCT Number NCT07634471
Lead Sponsor Merck Sharp & Dohme LLC
Conditions Follicular Lymphoma
Enrollment 960 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov